These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12176557)

  • 41. Comparative pharmacokinetics of cyclosporine A and cyclosporine G in renal allograft recipients.
    Gruber SA; Gallichio M; Rosano TG; Hughes SE; Singh TP; Lempert N; Conti DJ; Hasselbarth J; Freed BM; Stein D; Drusano G
    Transplant Proc; 1996 Apr; 28(2):892. PubMed ID: 8623449
    [No Abstract]   [Full Text] [Related]  

  • 42. Cyclosporine blood concentration at 2 hours (C(2)) from drug ingestion as the best single indicator of adequate cyclosporine immunosuppression in renal allograft recipients--a four-year follow-up.
    Baczkowska T; Serafinowicz A; Kukuła K; Nowacka-Cieciura E; Cieciura T; Deborska D; Gałazka Z; Rowiński W; Szmidt J; Durlik M; Lao M
    Transplant Proc; 2002 Mar; 34(2):556-7. PubMed ID: 12009622
    [No Abstract]   [Full Text] [Related]  

  • 43. Neoral C2 monitoring in solid organ transplantation.
    Levy GA
    Transplant Proc; 2004 Mar; 36(2 Suppl):392S-395S. PubMed ID: 15041373
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients.
    Gaspari F; Anedda MF; Signorini O; Amuchastegui SC; Perico N; Remuzzi G
    Transplant Proc; 1998 Aug; 30(5):1654-5. PubMed ID: 9723229
    [No Abstract]   [Full Text] [Related]  

  • 45. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
    Vathsala A; Lee WT; Jacob E; Woo KT
    Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
    [No Abstract]   [Full Text] [Related]  

  • 46. Cyclosporine trough levels in diabetic and nondiabetic renal transplant patients.
    Wadhawan S; Jauhari H; Singh S
    Transplant Proc; 2000 Nov; 32(7):1683-4. PubMed ID: 11119891
    [No Abstract]   [Full Text] [Related]  

  • 47. Cyclosporine neoral monitoring and its correlation with the "area under the curve".
    Sabbatiello R; Sgrosso JL; Schiavelli R; Castro C; Ahualli L; Pattin M; Vazquez MC
    Transplant Proc; 1996 Dec; 28(6):3378. PubMed ID: 8962317
    [No Abstract]   [Full Text] [Related]  

  • 48. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period.
    Amante AJ; Kahan BD
    Transplant Proc; 1996 Aug; 28(4):2162-3. PubMed ID: 8769187
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparative pharmacokinetic study of Neoral vs Sandimmun in Japanese stable renal allograft recipients.
    Takahara S; Ohta K; Ohashi Y; Namii Y; Uchida K; Okuyama A; Kainuma H; Takagi H; Takahashi K; Morikawa H
    Transplant Proc; 1999 Nov; 31(7):3089-92. PubMed ID: 10610595
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparative pharmacokinetic study of neoral versus Sandimmun in Japanese stable renal allograft recipients.
    Takahara S; Ohta K; Ohashi Y; Namii Y; Uchida K; Okuyama A; Kainuma H; Takagi H; Takahashi K; Morikawa H
    Transplant Proc; 2001 Jun; 33(4):2541-4. PubMed ID: 11406243
    [No Abstract]   [Full Text] [Related]  

  • 52. Study of the cyclosporine concentration at 2 hours in stable renal transplant patients and relation to body mass index.
    Hortal L; Fernández A; Losada A; Lorenzo M; Baamonde E; Plaza C; Gallego R; Vega N; Palop L
    Transplant Proc; 2001; 33(7-8):3110-1. PubMed ID: 11750337
    [No Abstract]   [Full Text] [Related]  

  • 53. Measurement of lymphocyte cyclosporine levels in transplant patients.
    Masri MA; Barbari A; Stephan A; Rizk S; Kilany H; Kamel G
    Transplant Proc; 1998 Nov; 30(7):3561-2. PubMed ID: 9838559
    [No Abstract]   [Full Text] [Related]  

  • 54. A critical appraisal of cyclosporine A pharmacokinetics in pediatric kidney transplantation using a microemulsion galenic formulation (Neoral).
    Foradori A; Pinto VM; Elberg A
    Transplant Proc; 1998 Aug; 30(5):1666-7. PubMed ID: 9723235
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparison of cyclosporine absorption profiles over a 12-month period in stable pediatric renal transplant recipients.
    Wigger M; Drückler E; Muscheites J; Stolpe HJ; Kundt G; Wacke R
    Transplant Proc; 2003 Jun; 35(4):1300-3. PubMed ID: 12826143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can three-times-a-day cyclosporine Neoral avoid cyclosporine toxicity in renal transplant recipients? A pharmacokinetic study.
    Swart N; Botha J; Tandon V; Michaels P; Pontin AR; Halkett J; Pascoe MD; Kahn D
    Transplant Proc; 2001; 33(7-8):3140-1. PubMed ID: 11750349
    [No Abstract]   [Full Text] [Related]  

  • 57. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U; Ullrich S; Roskos M; Misselwitz J
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [TBL] [Abstract][Full Text] [Related]  

  • 58. To keep a stable therapeutic level of cyclosporine during the early posttransplant period is important in graft survival.
    Ahn MS; Ha J; Yun IJ; Kim S; Lee JS; Kim S; Han JS; Ahn C; Choi Y; Cheong HI; Kim ST; Kim SJ
    Transplant Proc; 1996 Jun; 28(3):1316-7. PubMed ID: 8658675
    [No Abstract]   [Full Text] [Related]  

  • 59. Conversion from Sandimmune to Neoral in renal transplant: functional histopathological, and pharmacokinetic changes.
    Roessler E; Herrera S; Espinoza M; Ayala A; Reynolds E; González F; Espinoza O; Undurraga A; Muñoz R; Arcos O; Galaz G
    Transplant Proc; 1998 Aug; 30(5):1756-7. PubMed ID: 9723268
    [No Abstract]   [Full Text] [Related]  

  • 60. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
    Cole E; Deshpande R
    Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.